-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Amy Moore
-
Member Story: Dr. Amy Moore
Dr. Amy Moore—USA Dr. Amy Moore is the Director of Science and Research for the GO2 Foundation for Lung Cancer and based in the San Francisco Bay area, shares her thoughts on the current COVID-19 pandemic and what it means for the lung cancer community. I guess my perspective is a unique one because my doctorate…
-
Letter to the Editor: Patient-Driven Research
By Jill Feldman, EGFR Resisters Co-Founder Posted: December 11, 2019 Jill Feldman I was so glad to see the article by Dr. Amy Moore on PDX models in the October issue. As a Co-Founder of the EGFR Resisters, our collaboration with the GO2 Foundation for Lung Cancer is empowering patients to participate in studies that…
View ILCN Archives
Provider Resources
Popular Articles